UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. バセドウ眼症（グレーブス眼窩疾患：眼症）の治療 treatment of graves orbitopathy ophthalmopathy
2. 甲状腺機能正常型高サイロキシン血症および低サイロキシン血症 euthyroid hyperthyroxinemia and hypothyroxinemia
3. バセドウ眼症（グレーブス眼症：眼窩疾患）の病因および臨床的特徴 pathogenesis and clinical features of graves ophthalmopathy orbitopathy
4. 放射性ヨウ素による甲状腺機能亢進症の治療 radioiodine in the treatment of hyperthyroidism
5. 甲状腺機能亢進症およびバセドウ病の神経学的症状 neurologic manifestations of hyperthyroidism and graves disease

English Journal

Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.

Chen DY1, Schneider PF2, Zhang XS1, Luo XY3, He ZM4, Chen TH1.Author information 1Department of Nuclear Medicine of The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.2Clinic for Nuclear Medicine, University Hospital, Würzburg, Germany.3Ophthalmology Division, Guangdong General Hospital, Guangzhou, China.4Department of Internal Medicine of The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.AbstractAIMS: A significant association between radioiodine therapy (RIT) and the development or the worsening of pre-existing Graves' ophthalmopathy (GO) has been reported. This post-hoc analysis of 2 studies attempted to describe the changes observed in pre-existing or new-onset GO following RIT with the goal of euthyroidism rather than hypothyroidism and to describe the relationship GO changes and the final outcome.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.Exp Clin Endocrinol Diabetes.2014 Jan;122(1):1-6. doi: 10.1055/s-0033-1358484. Epub 2013 Nov 7.
AIMS: A significant association between radioiodine therapy (RIT) and the development or the worsening of pre-existing Graves' ophthalmopathy (GO) has been reported. This post-hoc analysis of 2 studies attempted to describe the changes observed in pre-existing or new-onset GO following RIT with the
PMID 24203649

Total thyroidectomy as primary definitive treatment for Graves' hyperthyroidism.

Snyder S1, Govednik C, Lairmore T, Jiang DS, Song J.Author information 1Department of Surgery, Scott & White Healthcare, The Texas A&M Health Science Center College of Medicine, Temple, Texas.AbstractThe objective of this study was to compare the results of total thyroidectomy (TT) for hyperthyroidism secondary to Graves' disease (GD) with TT for other benign thyroid diseases to determine if TT should be considered more often as first-line therapy for GD. Seven hundred eighty patients underwent TT for benign disease: 203 for GD, 56 for other hyperthyroidisms, and 521 for other benign diseases from March 1, 2003, to December 31, 2009. The perioperative results of these three groups were compared for demographics, blood loss, operative time, complications, and hospitalization. There were no significant differences among the three groups except the patients with GD were more likely to be younger (42 vs 56 vs 57 years; P < 0.001), have more blood loss (154 vs 99 vs 110 mL; P = 0.05), and were more likely to develop permanent hypoparathyroidism (1.0 vs 1.8 vs 0%; P = 0.03) when compared with other causes of hyperthyroidism and other benign thyroid diseases. Permanent recurrent laryngeal nerve injury did not occur in the GD group (0 vs 0 vs 0.4% nerves at risk; P = 0.69) with transient recurrent laryngeal nerve injury occurring in 1.7 versus 2.7 versus 3.1 per cent nerves at risk (P = 0.35). The lack of a euthyroid state preoperatively had no influence on surgical outcomes or complications. Eighty percent of the TTs for GD were done as same-day outpatient procedures. TT offers a safe, low-risk, and rapid cure for GD to justifiably be considered as a reasonable first-line therapy in selected patients with Graves' hyperthyroidism.
The American surgeon.Am Surg.2013 Dec;79(12):1283-8.
The objective of this study was to compare the results of total thyroidectomy (TT) for hyperthyroidism secondary to Graves' disease (GD) with TT for other benign thyroid diseases to determine if TT should be considered more often as first-line therapy for GD. Seven hundred eighty patients underwent
PMID 24351357

Total thyroidectomy for Graves' disease: compliance with American Thyroid Association guidelines may not always be necessary.

Shinall MC Jr1, Broome JT, Nookala R, Shinall JB, Kiernan C, Parks L 3rd, Solórzano CC.Author information 1Department of Surgery, Vanderbilt University Medical Center, Nashville, Nashville, TN. Electronic address: Ricky.shinall@vanderbilt.edu.AbstractBACKGROUND: Total thyroidectomy (TT) is the preferred operative approach to Graves' disease. Current guidelines of the American Thyroid Association call for the administration of potassium iodide (KI) and achievement of euthyroid state before operation. Small numbers and a mixture of operative approaches spanning several decades hinder previous operative series. We present the outcomes for TT at a single high-volume center.
Surgery.Surgery.2013 Nov;154(5):1009-15. doi: 10.1016/j.surg.2013.04.064. Epub 2013 Sep 26.
BACKGROUND: Total thyroidectomy (TT) is the preferred operative approach to Graves' disease. Current guidelines of the American Thyroid Association call for the administration of potassium iodide (KI) and achievement of euthyroid state before operation. Small numbers and a mixture of operative appro
PMID 24075271

Japanese Journal

症例初診時TSAb陽性でeuthyroid Graves' ophthalmopathyとの鑑別に難渋した特発性外眼筋炎の1例

松下幸司,岡田洋右,新生忠司 [他]
内科 114(2), 352-356, 2014-08
NAID 40020161441

シクロフォスファミドパルス療法が有効であった難治性甲状腺眼症の1例

谷川隆久,岡田洋右,田中良哉
産業医科大学雑誌 28(2), 185-191, 2006-06-01
甲状腺眼症はバセドウ病でよく認められる病態の一つである.グルココルチコイド療法と放射線療法はよく用いられ,最も有効な治療であるが両方の治療に抵抗性の症例もしばしば経験する.我々はこのような難治性の甲状腺眼症にシクロフォスファミドパルス療法が有効であった症例を経験したので報告する.症例は31歳の女性でバセドウ病発症時に眼症を伴っており,甲状腺ホルモンが正常化した後にも症状が持続していたため,グルココ …
NAID 110004729685